Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
FiercePharma7h
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Targeted Oncology6h
FDA Grants Fast Track Designation to Invikafusp Alfa in TMB-H Colorectal Cancer
Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...
earth21h
Forever chemicals alter gene expression in the brain
Forever chemicals or PFAS disrupt brain genes, reducing neuron survival and increasing cell death. Different compounds have ...
oncnursingnews2h
FDA Fast Tracks Invikafusp Alfa for TMB-High CRC
Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...
JCN Newswire7h
Where is the next Chinese drug that will make MNCs compete to grab orders?
HONG KONG, Jan 9, 2025 - (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.
Can Ozempic damage your optic nerve? Here’s what doctors say about a new study
A Danish study has found that semaglutide, which controls blood glucose while ensuring weight loss, is associated with a ...